Does lurbinectedin cause anemia?
Lurbinectedin (branded as Zepzelca) lists anemia as a common side effect, occurring in 42-66% of patients across clinical trials for small cell lung cancer.[1][2] It's typically grade 3-4 (severe) in 13-24% of cases, often requiring transfusions or dose adjustments.[1]
How common is anemia with lurbinectedin?
In the pivotal IMphase trial (n=405), anemia affected 66% of patients overall, with 24% experiencing severe (grade 3-4) drops in hemoglobin.[1][3] Real-world data from post-approval studies show similar rates, around 50-60%, linked to the drug's myelosuppressive effects on bone marrow.[2][4]
Why does lurbinectedin lead to anemia?
Lurbinectedin traps DNA in cancer cells and disrupts transcription, but it also suppresses hematopoiesis in bone marrow, reducing red blood cell production.[5] This is dose-dependent and peaks 1-2 weeks after infusion.[1]
How is lurbinectedin-induced anemia managed?
Guidelines recommend monitoring hemoglobin weekly, holding doses below 8 g/dL, and using transfusions or erythropoiesis-stimulating agents (ESAs) like epoetin if needed.[1][6] Dose reductions occur in 20-30% of cases; permanent discontinuation is rare (under 5%).[3]
Compared to other SCLC treatments
Lurbinectedin causes less severe anemia than topotecan (up to 40% grade 3-4) but more than immunotherapy like atezolizumab (10-15%).[1][7] Combinations with doxorubicin increase risk further.[2]
Patient risks and monitoring
Patients with pre-existing anemia or prior chemotherapy face higher risks; baseline hemoglobin under 10 g/dL predicts worse outcomes.[4] FDA labeling requires blood counts before each cycle.[1]
[1]: Zepzelca Prescribing Information (FDA)
[2]: Drugs.com - Lurbinectedin Side Effects
[3]: Trigo et al., Lancet Oncology (2020) - IMphase Trial
[4]: Farago et al., JCO (2022) - Real-World Data
[5]: Kaufman et al., Cancer Discovery (2018) - Mechanism
[6]: NCCN Guidelines - SCLC (v2.2023)
[7]: Rudin et al., NEJM (2019) - Topotecan Comparison